NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study

NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antiviral therapies, has recently announced encouraging results from a humanized animal study for its lead drug candidate, NV-387, targeting Measles. The study demonstrated a remarkable 130% increase in survival rates among humanized mice infected with a lethal dose of the virus, extending survival from 7.4 to 17 days without any observed toxicity. This breakthrough underscores the potential of NV-387 as a pioneering therapeutic solution in the fight against Measles, a disease that has seen a resurgence globally due to declining vaccine coverage.

The innovative approach of NV-387 involves mimicking human cell features to effectively bind and neutralize viruses, offering a broad-spectrum solution capable of targeting over 90% of human pathogens. With Measles cases on the rise worldwide, the development of NV-387 comes at a critical time, addressing the urgent need for effective treatment options beyond vaccination. Anil R. Diwan, PhD, highlighted the significance of these findings, stating, "NV-387 is on its way to become the very first drug to treat Measles," marking a potential turning point in antiviral therapy.

NanoViricides is now focused on advancing NV-387 into Phase II human clinical trials, with the aim of developing it as a treatment for a range of respiratory viral infections, including RSV, COVID-19, and influenza, in addition to Measles. The company's progress represents a significant step forward in the field of nanomedicine and antiviral research, offering hope for the development of effective treatments against some of the most challenging viral infections facing the global population today.